Prognostic role of miR-200c in various malignancies: a systematic review and meta-analysis.
MiR-200c expression is dysregulated in various malignancies and may predict the survival of patients with cancer, although the results of different studies conflict. Therefore, we conducted a meta-analysis to resolve this discrepancy. We queried the PubMed and Embase using multiple search strategies. Data were extracted from studies comparing overall survival and progression-free survival in patients with cancer with high and low levels of miR-200c expression. Fixed and random models were used where appropriate. A combined hazards ratio (HR) was calculated to estimate the association of high levels of miR-200c with survival. We selected 16 studies of 1485 participants for our final meta-analysis. Upregulated expression of miR-200c predicted significantly worse overall survival in patients with cancer (HR 1.51; 95% confidence interval [CI] 1.06-2.16, P = 0.023). Subgroup analysis indicated that high levels of miR-200c was associated with decreased survival of Caucasians and patients with gynecological tumors with pooled HR values of 1.82 (95% CI 1.27-2.26, P = 0.01) and 3.23 (95% CI 1.11-9.38, P = 0.032), respectively. Because of the absence of apparent heterogeneity, the combined HRs were 1.69 (95% CI 1.24-2.30, P = 0.001) for squamous cell carcinoma and 1.91 (95% CI 1.40-2.59, P < 0.001) for samples from peripheral blood. Increased expression of miR-200c significantly associated with shorter progression-free survival of patients with cancer (HR 2.37; 95% CI 1.47-3.81, P < 0.001). Our meta-analysis indicates that the level of miR-200c expression predicted survival of patients with cancer, particularly for Caucasians and patients with gynecological cancer. Increased expression of miR-200c predicted shorter survival of patients with squamous cell carcinomas. Our findings indicate that monitoring the levels of miR-200c in blood may be useful for following tumor progression as well as patients' prognosis.
Department of General Surgery, Chinese People's Liberation Army General Hospital 28 Fuxing Road, Beijing 100853, China.
Ke-Cheng
KC
Zhang
Department of General Surgery, Chinese People's Liberation Army General Hospital 28 Fuxing Road, Beijing 100853, China.
Hong-Qing
HQ
Xi
Department of General Surgery, Chinese People's Liberation Army General Hospital 28 Fuxing Road, Beijing 100853, China.
Jian-Xin
JX
Cui
Department of General Surgery, Chinese People's Liberation Army General Hospital 28 Fuxing Road, Beijing 100853, China.
Wei-Song
WS
Shen
Department of General Surgery, Chinese People's Liberation Army General Hospital 28 Fuxing Road, Beijing 100853, China.
Ji-Yang
JY
Li
Department of General Surgery, Chinese People's Liberation Army General Hospital 28 Fuxing Road, Beijing 100853, China.
Bo
B
Wei
Department of General Surgery, Chinese People's Liberation Army General Hospital 28 Fuxing Road, Beijing 100853, China.
Lin
L
Chen
Prognosis; cancers; meta-analysis; miR-200c; survival